Why GLP-1 drugs like Wegovy work for some but fail others in obesity treatment

New injectable drugs like Wegovy and Zepbound have changed how obesity is treated. These GLP-1 medications help some patients lose a large amount of weight, but results vary widely. Experts now stress that obesity is a complex condition requiring personalised approaches for long-term success.

For years, Anna Olson struggled with obesity that began in early childhood. After identifying her unique biological and behavioural triggers, she found success with GLP-1 drugs. Her case highlights how individual factors play a key role in treatment outcomes.

Dr. Lydia Alexander, former president of the Obesity Medicine Association, explains that responses to these drugs differ greatly. Gut microbiome composition, hormone receptor sensitivity, and other personal traits influence effectiveness. Not everyone achieves dramatic weight loss, even on the same medication.

Dr. Jennifer Manne-Goehler, a Harvard specialist in metabolic diseases, notes that about half of GLP-1 users lose 15% or more of their body weight. However, she warns that obesity is a chronic condition requiring ongoing management. The drugs are not a one-size-fits-all solution.

Within a few years, medical advances may allow more precise targeting of obesity treatments. Tools to pinpoint each person's specific obesity drivers could lead to truly personalised care plans. This shift would move beyond trial-and-error prescribing of GLP-1 medications.

While GLP-1 drugs have helped many patients, their effectiveness depends on individual biology and behaviour. Future developments in personalised medicine may improve outcomes by tailoring treatments to each person's needs. For now, experts urge realistic expectations and a focus on long-term health strategies.